ADVB · Advanced Biomed Inc. Common Stock

Advanced Biomed Inc. has executed a transformative strategic pivot from life sciences to artificial intelligence development, marked by the acquisition of Acellent Technologies (Hong Kong) Co. Limited, a firm led by incoming CEO Xiaomin Chen. The deal, completed on April 30, 2026, involved issuing 270,000 shares valued at $4.00 each to Chen as the sole shareholder, integrating AI expertise in financial-domain large language models and verification systems. Concurrently, the board appointed Chen, a 49-year-old AI veteran with experience at Google and prior roles building AI platforms, as CEO, director, and Chairman effective April 28, 2026, under an employment agreement providing $12,000 monthly salary plus eligibility for bonuses and benefits. This leadership shift followed a mutual separation with outgoing CEO Yi Lu, who received 39,999 fully vested shares as severance via a Termination Agreement dated April 28, 2026. The mutual nature underscores alignment on the pivot's necessity, with Lu resigning all positions without adversity. Both share issuances relied on Section 4(a)(2) exemptions, signaling rapid execution to bolster AI capabilities for investors eyeing sector growth.